Shandong WoHua Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") and all members of the board of directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
I. Review Procedure
The Company held the seventh meeting of the eighth board of directors on January 19, 2026, where the "Profit Distribution Plan for the Year 2025" was reviewed and approved. This proposal is subject to the approval of the shareholders' meeting. The relevant matters are hereby announced as follows:
II. Profit Distribution Plan for 2025
According to the audit by Zhongxi Accounting Firm (Special General Partnership), the net profit attributable to shareholders of the listed company for the year 2025 is RMB 95,715,292.65. After deducting the statutory surplus reserve of RMB 15,675,717.74 as required by the Company Law and the Articles of Association, adding the undistributed profit at the beginning of the year of RMB 73,886,556.43, and subtracting the profit distributed in the first half of 2025 of RMB 69,265,152.00, the profit available for distribution to shareholders in the consolidated financial statements is RMB 84,660,979.34.
The net profit of the parent company for 2025 is RMB 156,757,177.40. After deducting the statutory surplus reserve of RMB 15,675,717.74, adding the undistributed profit at the beginning of the year of RMB 19,443,217.59, and subtracting the profit distributed in the first half of 2025 of RMB 69,265,152.00, the profit available for distribution to shareholders of the parent company is RMB 291,259,525.25.
Based on the lower of the parent company and consolidated data, the profit available for distribution to shareholders is RMB 84,660,979.34. Considering the current operational and financial status of the Company, along with its strategic development plan, the Company proposes the following profit distribution plan for 2025: